Aimmune Therapeutics has reported positive results from its Phase III ARTEMIS trial of AR101 for the treatment of peanut allergy.

For the randomised, double-blind, placebo-controlled ARTEMIS clinical trial, Aimmune enrolled 175 children and adolescents aged 4 to 17 from 18 sites in France, Germany, Ireland, Italy, Spain, Sweden and the UK.

Patients underwent about six months of dose escalation and then three months at a daily therapeutic dose of AR101 at 300mg or placebo. This was followed by an exit double-blind, placebo-controlled food challenge.

The primary efficacy endpoint was the patients’ ability to tolerate a 1,000mg single dose of peanut protein.

“AR101 has the potential to become the first approved therapy for peanut allergy in both the US and Europe.”

The study met the primary endpoint of a statistically significant proportion of AR101-treated patients who tolerated the dose in a blinded exit challenge at month nine compared to placebo.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It also exceeded a 15% lower-bound of the 95% confidence interval of the difference between treatment arms for all endpoints.

Aimmune Therapeutics president and CEO Jayson Dallas said: “We are very pleased with the results of the ARTEMIS trial, which demonstrate that AR101 significantly improved the ability of patients to tolerate the 1,000mg dose of peanut protein in the exit food challenge, which correlates to at least three or four peanuts.

“AR101 has the potential to become the first approved therapy for peanut allergy in both the US and Europe, where up to two percent of children in many countries are affected.”

Based on the positive results, Aimmune proposes to submit a marketing authorisation application (MAA) for AR101 to the European Medicines Agency (EMA) this year.

Aimmune started a Phase II trial of AR101 with adjunctive dupilumab in October last year for the treatment of patients with peanut allergies as part of the collaboration with Regeneron and Sanofi.